Core Viewpoint - Biomerica, Inc. has received official registration from the UK Medicines & Healthcare products Regulatory Agency (MHRA) for its hp+detect™ diagnostic test, which detects Helicobacter pylori (H. pylori) bacteria, allowing it to be marketed in the UK [1][4] Group 1: Product and Market Impact - The hp+detect™ product detects H. pylori, which infects approximately 35% of the U.S. population and 45% of the population in Europe's five largest countries, and is a significant risk factor for gastric cancer [2][3] - H. pylori is responsible for peptic ulcer disease and is a primary driver of gastric cancer, which is the third most common cause of cancer-related death globally [3] - The WHO has classified H. pylori as a Class 1 carcinogen and among the 16 antibiotic-resistant bacteria that pose a major threat to human health, highlighting the need for accurate diagnostic tools [2][6] Group 2: Commercial Strategy and Future Plans - The MHRA registration is a significant commercial milestone for Biomerica, expanding its international reach into the UK market, which is important due to the high prevalence of H. pylori infection in Europe [4][6] - The company is actively engaging with UK partners to penetrate the diagnostic laboratory market and anticipates providing updates as agreements are finalized [6]